add_icon

Cipla

1,369.90
-8.50
(-0.62%)
Market Cap
1,10,656.66 Cr
PE Ratio
20.48
Volume
18,76,366.00
Day High - Low
1,398.40 - 1,363.80
52W High-Low
1,673.00 - 1,335.00
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
1,10,656.66 Cr
EPS
65.29
PE Ratio
20.48
PB Ratio
3.38
Book Value
407.53
EBITDA
7,989.80
Dividend Yield
1.16 %
Industry
Healthcare
Return on Equity
16.91
Debt to Equity
0.02
Forecast For
Actual

Company News

View All News
Caret
positive
Cipla Ltd has partnered with ImmunoACT to launch talicabtagene autoleucel, an anti-CD19 CAR-T cell therapy, for blood cancer treatment across select African markets including South Africa, Algeria and Morocco.
negative
Nomura reveals Cipla's recalled Lanreotide injection generates $120-150M annually, making it a top U.S. product, with resupply unlikely in H1 FY27 due to quality issues.
neutral
Cipla halts Lanreotide injection production due to supply partner issues, while Zydus Lifesciences receives FDA approval for Eltrombopag tablets. Biocon raises ₹4,150 crore through QIP.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,614.90
#1 3,87,468.60
36.89
#1 54,729.00
9.71
#1 10,980
2.89
26.52
5,983.00
1,58,829.85
64.20
9,712.00
18.67
2,191
35.10
29.62
3,954.60
1,33,841.63
62.86
11,539.40
6.99
1,911
30.46
56.71
1,369.90
#4 1,10,656.66
#4 20.48
#4 28,409.50
#8 7.12
#3 5,291
#7 3.71
23.28
2,142.10
97,850.87
22.76
22,909.50
13.74
3,306
#1 72.75
57.69
1,162.40
97,017.43
#1 16.98
33,741.20
16.73
5,725
-0.38
23.20
872.10
87,753.67
17.47
23,511.00
18.55
4,615
34.60
34.17
2,096.80
86,556.97
49.43
12,744.20
#1 20.90
2,007
-21.05
40.97
5,626.00
67,267.27
28.37
13,458.30
3.70
2,216
10.98
52.47
1,119.00
64,991.70
19.36
32,345.60
9.43
3,484
3.81
35.55
Growth Rate
Revenue Growth
7.12 %
Net Income Growth
27.33 %
Cash Flow Change
21.07 %
ROE
9.10 %
ROCE
2.32 %
EBITDA Margin (Avg.)
5.95 %

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
23 Jan 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
23 Jan 2026 1,512.50 1,378.40
11 Aug 2021 DIVIDEND Dividend
5.00 /share
09 Aug 2021 898.60 912.60
10 Aug 2022 DIVIDEND Dividend
5.00 /share
08 Aug 2022 937.55 1,029.55
26 Aug 2022 ANNUAL GENERAL MEETING Annual General Meeting
NA
26 Aug 2022 955.10 1,025.45
21 Jul 2023 DIVIDEND Dividend
8.50 /share
21 Jul 2023 943.95 1,056.20
02 Aug 2024 DIVIDEND Dividend
13.00 /share
02 Aug 2024 1,358.80 1,546.15
20 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
20 Aug 2024 1,358.80 1,575.50
29 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
29 Oct 2024 1,654.10 1,503.50
28 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
28 Jan 2025 1,510.25 1,395.90
13 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
13 May 2025 1,415.25 1,511.60
27 Jun 2025 DIVIDEND Dividend
3.00 /share
27 Jun 2025 1,511.60 1,512.75
27 Jun 2025 DIVIDEND Dividend
13.00 /share
27 Jun 2025 1,511.60 1,512.75
16 Jul 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
16 Jul 2025 1,511.60 1,490.90
25 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
25 Jul 2025 1,505.30 1,487.25
30 Oct 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
30 Oct 2025 1,527.10 1,581.10

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
The Wealth Company Arbitrage Fund Direct-Growth
0.69%
-17625
-1.19%
-0.52%
Nippon India Nifty 500 Low Volatility 50 Index Fund Direct-Growth
0.00%
-4132
-3.98%
-3.96%
Bandhan Healthcare Fund Direct - Growth
6.31%
4000
0.01%
6.31%
SBI Nifty100 Low Volatility 30 Index Fund Direct - Growth
3.35%
1456
0.24%
0.24%
JioBlackRock Nifty 50 Index Fund Direct-Growth
0.71%
1026
-0.01%
-0.01%
Bajaj Finserv Nifty 50 Index Fund Direct-Growth
0.71%
736
-0.01%
-0.01%
HDFC BSE India Sector Leaders Index Fund Direct-Growth
1.00%
653
0.04%
1.00%
DSP Nifty Healthcare Index Fund Direct-Growth
8.65%
300
0.10%
0.05%
Zerodha Nifty 50 Index Fund Direct - Growth
0.72%
289
0.00%
-0.02%
Bandhan BSE India Sector Leaders Index Fund Direct-Growth
0.99%
-212
0.03%
0.05%
Angel One Nifty 50 Index Fund Direct-Growth
0.71%
-119
-0.01%
0.00%
Nippon India BSE Sensex Next 30 Index Fund Direct-Growth
3.33%
-87
-0.06%
0.01%
Nippon India Nifty India Manufacturing Index Fund Direct - Growth
2.26%
85
-0.03%
0.05%
Groww Nifty 50 Index Fund Direct-Growth
0.71%
69
-0.01%
0.00%
Motilal Oswal BSE 1000 Index Fund Direct-Growth
0.41%
58
0.00%
0.01%
Invesco India Multicap Fund Direct-Growth
0.00%
0
0.00%
0.00%
HDFC NIFTY 100 Equal Weight Index Fund Direct - Growth
1.00%
0
0.00%
0.00%
Aditya Birla Sun Life Nifty 50 Equal Weight Index Fund Direct-Growth
1.99%
0
0.00%
0.02%
Aditya Birla Sun Life Nifty 50 Index Fund Direct-Growth
0.71%
0
0.00%
-0.01%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct-Growth
6.08%
0
0.00%
-0.68%
Aditya Birla Sun Life Retirement Fund - The 30s Plan Direct-Growth
1.81%
0
0.00%
-0.03%
Aditya Birla Sun Life Retirement Fund - The 40s Plan Direct-Growth
0.32%
0
0.00%
0.00%
Aditya Birla Sun Life Retirement Fund - The 50s Plan Direct-Growth
0.18%
0
0.00%
0.00%
Angel One Nifty Total Market Index Fund Direct - Growth
0.41%
0
0.00%
-0.01%
Axis Aggressive Hybrid Fund Direct-Growth
0.89%
0
0.00%
0.00%

Technical Indicators

RSI(14)
Neutral
23.28
ATR(14)
Less Volatile
25.70
STOCH(9,6)
Oversold
13.45
STOCH RSI(14)
Oversold
0.00
MACD(12,26)
Bearish
-11.67
ADX(14)
Strong Trend
31.05
UO(9)
Bearish
48.99
ROC(12)
Downtrend And Accelerating
-8.16
WillR(14)
Oversold
-93.51

About Cipla

Cipla Ltd is a leading Indian pharmaceutical company that manufactures, develops, and markets a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company operates in two segments: Pharmaceuticals and New ventures. Its product portfolio includes complex generics and drugs in respiratory, anti-retroviral, urology, cardiology, anti-infective,...more
Chairperson NameY K Hamied